Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C
Front Immunol. 2025; 16:1519866.
PMID: 39958330
PMC: 11827429.
DOI: 10.3389/fimmu.2025.1519866.
Srimathi S, Ignacio M, Rife M, Tai S, Milton D, Scull M
Lab Chip. 2025; .
PMID: 39907221
PMC: 11796355.
DOI: 10.1039/d4lc00940a.
Rendon-Marin S, Rincon-Tabares D, Tabares-Guevara J, Arbelaez N, Forero-Duarte J, Diaz F
Vaccines (Basel). 2024; 12(10).
PMID: 39460307
PMC: 11511104.
DOI: 10.3390/vaccines12101140.
Lim C, Komarasamy T, Binti Adnan N, Radhakrishnan A, Balasubramaniam V
Influenza Other Respir Viruses. 2024; 18(3):e13276.
PMID: 38513364
PMC: 10957243.
DOI: 10.1111/irv.13276.
Li R, Chang Z, Liu H, Wang Y, Li M, Chen Y
J Nanobiotechnology. 2024; 22(1):44.
PMID: 38291444
PMC: 10825999.
DOI: 10.1186/s12951-024-02293-y.
In Vivo Validation of Novel Synthetic Peptide-Based Vaccine Candidates against Strains in BALB/c Mice.
Bibi N, Wajeeha A, Mukhtar M, Tahir M, Zaidi N
Vaccines (Basel). 2023; 11(11).
PMID: 38005983
PMC: 10675187.
DOI: 10.3390/vaccines11111651.
Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus.
Heng W, Lim H, Tan K, Poh C
Pharm Res. 2023; 40(8):1999-2025.
PMID: 37344603
DOI: 10.1007/s11095-023-03540-x.
Expression of Influenza M2e-NP Recombinant Fusion Protein in BL21 (DE3) and Its Binding to Antibodies.
Tan M, Mohamed Alitheen N, Tan W, Yap W
Vaccines (Basel). 2022; 10(12).
PMID: 36560475
PMC: 9784878.
DOI: 10.3390/vaccines10122066.
Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine.
Quach H, Ovsyannikova I, Poland G, Kennedy R
Sci Rep. 2022; 12(1):15401.
PMID: 36100624
PMC: 9470075.
DOI: 10.1038/s41598-022-19679-3.
Peptides for Vaccine Development.
Hamley I
ACS Appl Bio Mater. 2022; 5(3):905-944.
PMID: 35195008
PMC: 9384901.
DOI: 10.1021/acsabm.1c01238.
Immunopeptidomic analysis of influenza A virus infected human tissues identifies internal proteins as a rich source of HLA ligands.
Nicholas B, Bailey A, Staples K, Wilkinson T, Elliott T, Skipp P
PLoS Pathog. 2022; 18(1):e1009894.
PMID: 35051231
PMC: 8806059.
DOI: 10.1371/journal.ppat.1009894.
Developing a Live Probiotic Vaccine Based on the L3 Strain Expressing Influenza Neuraminidase.
Desheva Y, Leontieva G, Kramskaya T, Gupalova T, Losev I, Kuleshevich E
Microorganisms. 2021; 9(12).
PMID: 34946050
PMC: 8707194.
DOI: 10.3390/microorganisms9122446.
Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.
Li M, Guo P, Chen C, Feng H, Zhang W, Gu C
Front Immunol. 2021; 12():745625.
PMID: 34712234
PMC: 8546227.
DOI: 10.3389/fimmu.2021.745625.
Conserved Sequence Analysis of Influenza A Virus HA Segment and Its Application in Rapid Typing.
Lin Q, Ji X, Wu F, Ma L
Diagnostics (Basel). 2021; 11(8).
PMID: 34441263
PMC: 8393347.
DOI: 10.3390/diagnostics11081328.
In silico design of a multi-epitope peptide construct as a potential vaccine candidate for Influenza A based on neuraminidase protein.
Behbahani M, Moradi M, Mohabatkar H
In Silico Pharmacol. 2021; 9(1):36.
PMID: 33987075
PMC: 8112742.
DOI: 10.1007/s40203-021-00095-w.
Deciphering the Subtype Differentiation History of SARS-CoV-2 Based on a New Breadth-First Searching Optimized Alignment Method Over a Global Data Set of 24,768 Sequences.
Lin Q, Huang Y, Jiang Z, Wu F, Ma L
Front Genet. 2021; 11:591833.
PMID: 33505425
PMC: 7831388.
DOI: 10.3389/fgene.2020.591833.
The Next Generation of Influenza Vaccines: Towards a Universal Solution.
McMillan C, Young P, Watterson D, Chappell K
Vaccines (Basel). 2021; 9(1).
PMID: 33430278
PMC: 7825669.
DOI: 10.3390/vaccines9010026.
Masking terminal neo-epitopes of linear peptides through glycosylation favours immune responses towards core epitopes producing parental protein bound antibodies.
Pon R, Marcil A, Chen W, Gadoury C, Williams D, Chan K
Sci Rep. 2020; 10(1):18497.
PMID: 33116268
PMC: 7595224.
DOI: 10.1038/s41598-020-75754-7.
Peptides to combat viral infectious diseases.
Al-Azzam S, Ding Y, Liu J, Pandya P, Ting J, Afshar S
Peptides. 2020; 134:170402.
PMID: 32889022
PMC: 7462603.
DOI: 10.1016/j.peptides.2020.170402.
Construction and Immunogenicity of a Novel Multivalent Vaccine Prototype Based on Conserved Influenza Virus Antigens.
Kirsteina A, Akopjana I, Bogans J, Lieknina I, Jansons J, Skrastina D
Vaccines (Basel). 2020; 8(2).
PMID: 32344753
PMC: 7349063.
DOI: 10.3390/vaccines8020197.